Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Raclopride is a synthetic small molecule classified as a typical antipsychotic and acts as a selective antagonist at dopamine D2 receptors, with moderate selectivity for D3 receptors and much lower affinity for D4 and D1 receptors. It is primarily used in research settings, including clinical trials for Parkinson's disease, schizophrenia, and neuroimaging studies. Radiolabeled forms of raclopride (such as ^11C-raclopride) are widely used in positron emission tomography (PET) to assess dopamine receptor density and function in the brain. Its mechanism involves blocking the action of dopamine at the D2 receptor site, which can modulate psychotic symptoms or be used to study neurological disorders[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on raclopride.